A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma

Phase 3 Active not recruiting 633 enrolled Amgen

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to assess the efficacy, safety, and immunogenicity of ABP 206 compared with Nivolumab in Subjects with Treatment-Naïve Unresectable or Metastatic Melanoma.

Timeline

Start: 2023-11-02
Primary completion: 2028-01-25
Completion: 2028-01-25

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Nivolumab	Monoclonal antibody	—	Intravenous

A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma

Summary

Timeline

Drugs

Indications